The global demand for Lung Disease Therapeutics Market is presumed to reach the market size of nearly USD 116.41 BN by 2030 from USD 80.41 BN in 2022 with a CAGR of 4.7% under the study period 2023 - 2030.
Lung disease therapeutics refers to the medical treatments and interventions aimed at managing and treating various lung-related disorders and diseases. It covers conditions affecting the respiratory system, including both acute and chronic diseases that impact lung function and overall respiratory health. These therapeutics can involve various approaches, including medications, therapies, changes in lifestyle, and, in some cases, surgical interventions.
The increasing prevalence of lung diseases, driven by factors like pollution and ageing populations, fuels the demand for effective treatments. Environmental factors, technological advancements, and research contribute to the growing need for therapies. Personalized medicine and emerging biopharmaceuticals, such as targeted therapies, enhance treatment options. Rising healthcare expenditure, early diagnosis awareness, and stricter regulatory standards play significant roles. The COVID-19 pandemic highlighted respiratory health's importance and accelerated research in the field. Global initiatives, healthcare infrastructure development, and a patient-centric approach further influence the market. As patients and healthcare professionals seek improved therapies, the market is anticipated to evolve.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of lung disease therapeutics. The growth and trends of lung disease therapeutics industry provide a holistic approach to this study.
This section of the lung disease therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Disease Type
By Drug Class
By Distribution Channel
This section covers the regional outlook, which accentuates current and future demand for the Lung Disease Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lung Disease Therapeutics market include GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F.Hoffam La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, PharmAkea Therapeutics, IQVIA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . LUNG DISEASE THERAPEUTICS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Disease Type
3.7.2 Market Attractiveness Analysis By Drug Class
3.7.3 Market Attractiveness Analysis By Distribution Channel
3.7.4 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE
5.1 Overview by Disease Type
5.2 Historical and Forecast Data
5.3 Analysis by Disease Type
5.4 Asthma Historic and Forecast Sales by Regions
5.5 Chronic Obstructive Pulmonary Disease (COPD) Historic and Forecast Sales by Regions
5.6 Lung Cancer Historic and Forecast Sales by Regions
5.7 Other Lung Disease Historic and Forecast Sales by Regions
6 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS
6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Corticosteroids H ...